Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors
Recruiting
N/A
Interventional Study
Olanzapine
Breast Cancer
Dexamethasone
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female patients ≥18 years.
* Stage I-III breast cancer.
* Scheduled to receive AC chemotherapy.
* Presence of metabolic risk factors (diabetes, prediabetes, obesity, metabolic syndrome).
* ECOG performance status ≤2.
Exclusion Criteria:
* Recent systemic corticosteroid use.
…
Contacts